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INTRODUCTION
Renal cell carcinoma (RCC) is the most common tumor of the kidney. After diagnosis, 20–30% of
patients will relapse, with a high probability of death from cancer-related causes. The development
of non-invasive biomarkers will allow the identification of patients with a high risk of recurrence
after radical or partial nephrectomy and will improve the assessment of tumor response to targeted
therapy or immunotherapy. The search for non-invasive diagnostic techniques represents one of
themost difficult challenges for cancer researchers. The contemporary scenario includes a variety of
strategies that share the aim of maximally reducing the impact of the diagnosis on patients’ quality
of life (QoL). In this context, liquid biopsy offers a promising perspective for cancer diagnosis and
monitoring, with several advantages compared to traditional diagnostic procedures (1). Indeed, it
can be more frequently performed and allows for better tracking of tumors and mutations over a
period of time (1). Moreover, it has been showed that genomic profiles of liquid biopsies can match
very closely with the corresponding tumors (2).
The liquid biopsy of circulating tumor cells (CTCs), which belong to the larger family
of circulating rare cells (CRC), has been validated and approved by the US Food and Drug
Administration (FDA) as a useful prognostic tool in a variety of cancer types (3). This is based
not only on the ability of CTCs to be a mirror of tumor heterogeneity but also on the possibility
to combine the genetic and transcriptomic status of single CTCs (4) with epigenome analyses (5).
Although CTCs have received great attention based on their potential in evaluating the status of
localized and metastatic diseases, their clinical implementation is not yet widespread.
In the last decade, several studies have investigated the clinical and pathological significance
of CTC numbers and characteristics in patients with urogenital cancers (6, 7). In view of the
increasing number of dedicated clinical trials, genitourinary tumors represent the next urgent
field of application of molecular diagnostics and drug discovery after gastro-intestinal and
thoracic oncology. Among these tumors, the absence of reliable predictive biomarkers in RCC
prevents the proper selection of patients who will benefit from any one of the three main drug
categories approved for treating this disease: (1) anti-vascular endothelial growth factor (VEGF)
monoclonal antibodies (i.e., bevacizumab) or tyrosine kinase inhibitors (i.e., sunitinib, sorafenib,
pazopanib, axitinib, cabozantinib, tivozanib, and lenvatinib); (2) immune checkpoint inhibitors
[i.e., anti-programmed death(PD)-1 Nivolumab alone or in combination with anti-cytotoxic
T-lymphocyte antigen (CTLA)-4]; and (3) Mammalian target of rapamycin (mTOR) inhibitors
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(i.e., everolimus and temsirolimus). In this manuscript we
describe the emerging data on the role of CTCs in the diagnosis
and treatment of RCC, focusing on their future applicability in
daily clinical practice.
INTRA- AND INTER-TUMOR
HETEROGENEITY IN RCC
Intratumoral heterogeneity—in terms of somatic mutations,
chromosome aberrations, and tumor gene expression—is a
characteristic feature of clear cell RCC (8–11). These alterations
are primarily centered around the Von Hippel–Lindau (VHL)
gene and include LOH at 3p and epigenetic silencing. VHL
inactivation is a crucial event in the majority of clear cell RCC
and represents the only ubiquitous event, in contrast from the
other genetic and/or epigenetic aberrations reported which are
just subclonal (12–14). In this setting, Xu et al. firstly revealed
by single-cell exome sequencing in a single patient that <30%
of gene alterations are common to multiple cells within tumor
tissue, whilst the majority are only cell-specific (15). In the
same view, activated drug target pathways have been shown to
be considerably variable within the same tumor and between
primary RCC and lung metastases (16).
The rate of patients with late-relapsing disease (>5 y after
radical or partial nephrectomy) (17–19) and the common
intravenous tumor embolization (20) are just two of a series
of clear signs suggesting that CTCs may provide fundamental
information to optimize RCC diagnosis and evaluate tumor
response to therapy and progression.
CTC ISOLATION AND
CHARACTERIZATION IN RCC
The collection, identification, enrichment, and analysis of CTC
require the use of different methods, including the following: (1)
Epithelial or non-epithelial marker-dependent isolation; (2) RT-
PCR-based methods; (3) and morphological- and cell size-based
detection (21).
The first method consists of the detection of CTCs
through epithelial markers, such as the epithelial cell adhesion
molecule (EpCAM, Figure 1). EpCAM is a transmembrane
glycoprotein involved in cell signaling, migration, proliferation,
and differentiation (22). The number of CTCs that can be isolated
by EpCAM is usually low (23). This is based on the biological
behavior of clear cell RCC, which often transdifferentiates
through a process named “epithelial-to-mesenchymal transition
(EMT),” a morphological transformation that is phenotypic of
RCC cells (24, 25) and that leads to the loss of their epithelial
antigens and the acquisition of mesenchymal features (i.e.,
vimentin expression). Detecting EMTmarkers on CTCs provides
fundamental information on the status of the disease, considering
the straight association between EMT and the prognosis of
RCC patients (24) as well as its role in the acquisition of
invasive properties and resistance to anti-VEGF TKIs (24).
More recently, antibodies directed against membrane carbonic
anhydrase 9 (CA9/CAIX) and CD147 [a widely expressed
membrane glycoprotein involved in matrix metalloproteinase
induction, cell adhesion and T cell activation (26)] have been
developed to increase the number of selected CTCs in RCC
patients (Figure 1). Indeed, Liu et al. reported that while EpCAM
was found only in about 18% of clear cell RCC tumors, CAIX,
and CD147 were present in more than 97% of samples (27).
The second method is based on the RT-PCR approach.
The three main targets of this technique are CAIX, VHL and
Cadherin-6 (CDH-6) (Figure 1).VHL gene alterations detected in
tumor samples have reported concordance with those identified
on peripheral blood in about 75% of cases (28). On the other
hand, CDH-6 gene expression by RT-PCR has been observed in
45% of clear cell RCC blood samples (29).
The third method is built upon size-based blood filtration
combined with morphological and genetic analyses. The need
to associate different techniques derives from the evidence that
cytomorphological classification alone is not sufficient to detect
CTCs in RCC patients (30). Interestingly, the use of these
combined methods has enabled the detection of the presence of
circulating clusters with a core of cancer cells surrounded by an
external coating of endothelial cells (31).
The survival mechanisms underlying the circulation and
migration of CTCs depend on multiple factors. Their biological
characteristics, genetic alterations, epithelial mesenchymal
transition, and cancer stem cell properties are internal factors
that influence their survival. Great importance is now also
being attributed to the external factors in the bloodstream
microenvironment, consisting of platelets, immune cells,
cytokines, and circulating tumor microemboli (CTM) (32).
CTM are composed by cell clusters, from two to more than
50 CTCs, together with leukocytes, cancer-associated fibroblasts,
endothelial cells, and platelets (33). CTM demonstrated high
metastatic potential by inhibiting apoptosis, promoting cell
clonal proliferation, conferring resistance to shear stress, and
protecting the innermost cells from immune surveillance from
the identification of NK cells and their cytolytic activity (34).
Testing the expression of Ki-67 on CTCs and CTMs has revealed
a sharp contrast between CTCs (Ki-67 positive) and CTMs (all
negative for Ki-67), even in patients with Ki67 (+) CTCs (35).
This gives rise to the hypothesis that CTMs, in comparison to
CTCs, may have the capability to remain inactive and “dormant”
for long time periods, inhibiting apoptosis and cell destruction
in the bloodstream. They may also have the capacity to confer
resistance to cytotoxic drugs for cells within CTM, as observed
by Hou et al. in patients with non-small–cell lung cancer (36).
Colorectal cancer patients with CTMs in their blood have a
shorter survival period than patients with only CTCs detected
(37). Similar results were obtained in blood samples from
gastric cancer patients, in which the presence of CTMs was
an independent predictor of shorter PFS and OS in stage IV
patients in multivariate analysis (38). Detection of CTM has
emerged as a valuable tool to improve the prognostic significance
of liquid biopsy (39) (Figure 2). Comparing the epigenomes of
CTC clusters and single CTCs, Gkountela et al. demonstrated
that CTC clusters are enriched with binding sites for several
key transcription factors (TF)—such as OCT4, NANOG, and
SOX2—that confer to clusters stem cell features, whereas single
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FIGURE 1 | Circulating tumor cells (CTCs) in renal cell carcinoma microenvironment. CAIX, Carbonic anhydrase 9; CDH6, Cadherin-6; EpCAM, Epithelial cell
adhesion molecule.
CTC have enrichment in different sets of TF. Moreover, stem cell
TF binding is lost when clusters are dissociated into single cells
via Na+/K+ ATPase inhibitors such as digitoxin. In xenograft
mouse models generated using ex vivo expanded CTC lines,
administration of digitoxin significantly inhibited the capacity of
CTC clusters to generate metastases (40, 41). These results open
an area of new research and new therapeutic targets.
NEW METHODS OF DETECTION
New methods of isolation and analysis such as subtraction
enrichment (SE) combined with immunostaining-fluorescence
in situ hybridization (iFISH) are being developed to better
characterize CTCs. With this method, independent of cell size
variation, and free of hypotonic damage as well as anti-EpCAM
perturbing, it is possible to karyotype chromosome ploidy of
CTCs and phenotype multi-protein expression. Among different
cancers, an aneuploid chromosome 8 (tetraploid or polyploid)
identified a positive CTC (42–44). This allows for efficient
enrichment, identification, and characterization of both large
and small size CTCs as well as CTM in various biofluid
samples including cerebrospinal fluid (CSF). Unlike conventional
methodologies, SE-iFISH enables the characterization of different
heterogeneous CTC subtypes classified by both chromosome
ploidy and the expression of biomarkers (44). Broncy et al.
recently applied single-cell genetic analysis after isolation by
SizE of Tumor/Trophoblastic cells (ISET R©) in order to assess
the specificity and sensitivity of cytopathology. They performed
single cell analysis targeted to VHLmutations in all the 205 CRCs
identified by cytopathology in the blood of 29 ccRCC patients
after ISET filtration. They found a complete (100%) specificity of
the cytopathological approach in the identification of circulating
cancer cells (CCC) with a low sensitivity (35%) compared to
genetic analysis (72%) (45, 46).
A novel straight microfluidic chip technology to focus and
capture CTCs has been applied in head and neck cancer patients.
The microchip is designed based on inertial migration of cells in
a straight microchannel and allow to isolate single CTCs, CTCs
clusters, and CTM by a size-based method, with high recovery
efficiencies and low background cell contamination (47, 48).
FUTURE PERSPECTIVES
In future years, technical advances should aim to isolate a greater
number of CTCs in metastatic patients than in patients with
localized disease and to find the same mutations present in the
correspondent histologic sample or, especially, in the metastatic
cohort. In our opinion, this could be realized by improving
the connection between cytomorphological and genetic analyses,
thus overcoming the limits of present techniques, which can be
challenging and time-consuming. Indeed, the specificity of CAIX
and CDH-6 for CTCs in RCC patients is poor and could be
increased only by the design of studies focused on comparing
CTCs isolated from patients with clear cell and from patients with
benign kidney diseases or healthy volunteers.
We hope that in future years whole genome, transcriptome,
and proteome analyses of single cells could lead to an increase
in our knowledge of tumor heterogeneity and acquired drug
resistance. In the localized RCC setting, CTCs could have
potential as a surveillance biomarker for disease recurrence.
Earlier detection of metastatic RCC, prior to the onset of
symptoms, may lead to improved clinical outcomes. In patients
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FIGURE 2 | Survival mechanisms and influence factors of CTCs. Copyright © 2018 Wang et al. (32). This is an open access article distributed under the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
with metastatic disease, CTC analysis could be used to select
patients for biomarker-guided clinical trials. As in colorectal
cancers, the mutational profile of metastatic RCC could evolve
after treatment progression, developing an acquired resistance
to therapy potentially investigable in a non-invasive way with
CTCs. Moreover, the introduction of data on CTCs within the
TNM classification represents another step forward on the route
of personalized medicine for RCC patients.
CONCLUSIONS
RCC may benefit from the development of non-invasive and
reliable biomarkers, enabling early and timely personalized
treatment changes. The introduction of CTC analysis
within daily clinical practice for patients with RCC seems
still far at the moment. However, the advances obtained
in the last 5 years in isolating and analyzing CTCs
bring optimism about the future therapeutic landscape in
RCC patients.
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